Product Details

Teva-Febuxostat

Febuxostat
80 mg
Tablet


DIN/PIN/NPN

02466198

Manufacturer

Teva Canada Limited

Formulary Listing Date

2019-12-20  

Unit Price

1.3515

Amount MOH Pays

1.3515

Coverage Status

Off-Formulary Interchangeable Exceptional Access Program Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

M04AA03

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02357380 Uloric NA NA
02466198 Teva-Febuxostat 1.3515 1.3515
02473607 Mar-Febuxostat 1.3515 1.3515
02490870 Jamp-Febuxostat 1.3515 1.3515
02533243 Auro-Febuxostat 1.3515 1.3515
02539837 Febuxostat 1.3515 1.3515
 

LU Clinical Criteria

NO  

EAP Criteria

Therapeutic Class Reimbursement Criteria
Gout

Febuxostat

  • Brand(s): Generics of Uloric (see formulary OFIs)
  • Dosage Form/Strength: 80 mg
  • Updated: September 29, 2022

To lower serum uric acid levels, where recommended according to clinical guidelines, in patients with gout or hyperuricemia meeting at least one of the following: 

  1. Patient has experienced an inadequate response to maximum tolerated doses of allopurinol; OR 

  1. Patient has experienced a hypersensitivity reaction to allopurinol; OR 

  1. Patient has documentation of an absolute contraindication to allopurinol.

Patients who have experienced severe intolerances to allopurinol not meeting the above criteria will be considered on a case-by-case basis. 

Duration of approval: 1 year 

Renewal of funding will be considered for patients where there is objective evidence of clinical benefit from the use of febuxostat. 

Renewal approval period: 5 years

EAP Drug Request Form:

Standard Form for EAP Drug Requests

Product Monograph

View Monograph